



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Andrea G. Cochran et al. Serial No.: 09/592,695 Filed: June 13, 2000 For: Structured Peptide Scaffold for Displaying Turn Libraries on Phage	Group Art Unit: 1627 Examiner: T. Prasthofer CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on October 29, 2001 Eileen Ly
--	---

TECH CENTER 1600/2901
JAN 22 2001

RECEIVED

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This is responsive to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures dated September 27, 2001. Transmitted herewith are the following documents:

1. A substitute Sequence Listing, in paper copy and a computer readable diskette.
2. Certificate Re: Sequence Listing Response Under 37 CFR §1.821(f) and (g)
3. Copy of Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.

The substitute Sequence Listing is submitted to correct errors in the originally submitted "Sequence Listing". These errors, which mainly relate to "feature" information of various n's or Xaa's contained in subject sequences, have been identified in the Notice to Comply (a copy attached hereto), and are hereby corrected in compliance with the requirements of 37 CFR 1.821-1.825. SEQ ID NO:1 is hereby amended to replace Xaa at position 4 (which stands for 3-12 L-form amino acids as originally disclosed) with four specific amino acids Glu, Gly, Asn and Lys. The specific designation of Xaa at position 4 as GluGlyAsnLys is described in the specification at, for example, page 10, lines 16-21. Therefore, the replacement does not constitute new matter.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: October 29, 2001

By: Steven X. Cui

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674



09157

PATENT TRADEMARK OFFICE



SKC/CK
**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/592,695

06/19/00

DOCHIRAN

A

P1762R1

STEVEN X CUI
GENENTECH INC
1 DNA WAY
SOUTH SAN FRANCISCO CA 94080-4980

HM22/0927

EXAMINER

BRASTHOFFER, T

ART UNIT

PAPER NUMBER

1-37

DATE MAILED:

09/27/01

RECEIVED

OCT 04 2001

GENENTECH, INC.
LEGAL DEPT.

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

CALENDARED/CK

Comply

27 OCT 01

DUE DATE



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/592,695	06/13/00	Andrea G. Cochran	P1762 R1

EXAMINER	
Thomas Prasthofer	
ART UNIT	PAPER NUMBER
1627	9

Please find below a communication from the EXAMINER in charge of this application

Failure to Comply with Sequence Rules

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.


APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner, whose telephone number is (703) 308-4548. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner, whose telephone number is (703) 308-2439. The fax number for the organization where this application or proceeding is assigned is (703) 308-2742.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Thomas Prasthofer


September 25, 2001


DR. JYOTHSNA VENKAT PH.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ ~~An initial or~~ substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ ~~An initial or~~ substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support


Technical Assistance.....703-287-0200

To Purchase PatentIn Softwar703-306-2600


PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Koroma

BIOTECHNOLOGY
SYSTEMS
BRANCH



**RAW SEQUENCE LISTING
ERROR REPORT**



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

09/592,695

Source:

1627

Date Processed by STIC:

3/16/2001

#8

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:


Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

<http://www.uspto.gov/web/offices/pac/checker>



Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION


SERIAL NUMBER: 09/592,695

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☐ Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 ☐ Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 ☐ Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 ☐ Misaligned Amino Acid Numbering The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 ☐ Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 ☒ Variable Length Sequence(s) 1 contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
- 7 ☐ PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 8 ☐ Skipped Sequences (OLD RULES) Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 ☐ Skipped Sequences (NEW RULES) Sequence(s) ____ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 10 ☐ Use of n's or Xaa's (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 ☐ Use of <213>Organism (NEW RULES) Sequence(s) ____ are missing this mandatory field or its response.
- 12 ☒ Use of <220>Feature (NEW RULES) Sequence(s) 1 are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 ☐ PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.

1627



RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001
TIME: 15:33:38

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03162001\I592695.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: Cochran, Andrea G.
4 Skelton, Nicholas J.
5 Starovasnik, Melissa A.
7 <120> TITLE OF INVENTION: Structured Peptide Scaffold For Displaying Turn
8 Libraries On Phage
10 <130> FILE REFERENCE: P1762R1 US
12 <140> CURRENT APPLICATION NUMBER: US 09/592,695
13 <141> CURRENT FILING DATE: 2000-06-13
15 <150> PRIOR APPLICATION NUMBER: US 60/139,017
16 <151> PRIOR FILING DATE: 1999-06-14
18 <160> NUMBER OF SEQ ID NOS: 25
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 7
22 <212> TYPE: PRT
23 <213> ORGANISM: Artificial Sequence *see item 12 on Error Summary Sheet*
25 <220> FEATURE:
26 <223> OTHER INFORMATION: Xaa at positions 3 and 5 are selected from the group consisting of amino
27 acids Trp, Tyr, Phe, Leu, Met, Ile and Val;
29 <220> FEATURE:
W--> 30 <221> NAME/KEY: Artificial Sequence *These are not responses shown in WIPO Standard ST.25, Appendix 1, Tables 5*
31 <222> LOCATION: Full
32 <223> OTHER INFORMATION: Xaa at positions 2 and 6 are selected from the group consisting of amino
33 acids Trp, Tyr, Phe, His, Ile, Val and Thr;
35 <220> FEATURE:
W--> 36 <221> NAME/KEY: Artificial Sequence3 *not in WIPO Standard ST.25 see 1.823 of new Sequence Rule*
37 <222> LOCATION: Full
38 <223> OTHER INFORMATION: Xaa at position 4 stands for (3-12) L-form amino acids.
40 <220> FEATURE:
W--> 41 <221> NAME/KEY: unsure *These locations have been identified above*
42 <222> LOCATION: 2-6
43 <223> OTHER INFORMATION: unknown amino acid
45 <400> SEQUENCE: 1
W--> 46 Cys Xaa Xaa Xaa Xaa Xaa Cys
47 1 5
49 <210> SEQ ID NO: 2
50 <211> LENGTH: 10
51 <212> TYPE: PRT
52 <213> ORGANISM: Artificial Sequence
54 <220> FEATURE:
55 <223> OTHER INFORMATION: turn peptide
57 <400> SEQUENCE: 2
58 Cys Thr Trp Glu Gly Asn Lys Leu Thr Cys
59 1 5 10
61 <210> SEQ ID NO: 3
62 <211> LENGTH: 12
63 <212> TYPE: PRT
64 <213> ORGANISM: Artificial Sequence

RECEIVED

MAR 23 2001

TECH CENTER 1600/2900

RAW SEQUENCE LISTING

DATE: 03/16/2001

PATENT APPLICATION: US/09/592,695

TIME: 15:33:38

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03162001\I592695.raw

```

66 <220> FEATURE:
67 <223> OTHER INFORMATION: turn peptide
69 <400> SEQUENCE: 3
70 Ser Cys Thr Trp Glu Gly Asn Lys Leu Thr Cys Lys
71   1           5           10
73 <210> SEQ ID NO: 4
74 <211> LENGTH: 10
75 <212> TYPE: PRT
76 <213> ORGANISM: Artificial Sequence
78 <220> FEATURE:
79 <223> OTHER INFORMATION: turn peptide
81 <400> SEQUENCE: 4
82 Cys Gly Asn Gln Gly Ser Phe Leu Thr Cys
83   1           5           10
85 <210> SEQ ID NO: 5
86 <211> LENGTH: 10
87 <212> TYPE: PRT
88 <213> ORGANISM: Artificial Sequence
90 <220> FEATURE:
91 <223> OTHER INFORMATION: turn peptide
93 <400> SEQUENCE: 5
94 Cys Thr Trp Gln Gly Ser Phe Leu Thr Cys
95   1           5           10
97 <210> SEQ ID NO: 6
98 <211> LENGTH: 12
99 <212> TYPE: PRT
100 <213> ORGANISM: Artificial Sequence
102 <220> FEATURE:
103 <223> OTHER INFORMATION: turn peptide
105 <400> SEQUENCE: 6
106 Ser Cys Gly Asn Gln Gly Ser Phe Leu Thr Cys Lys
107   1           5           10
109 <210> SEQ ID NO: 7
110 <211> LENGTH: 12
111 <212> TYPE: PRT
112 <213> ORGANISM: Artificial Sequence
114 <220> FEATURE:
115 <223> OTHER INFORMATION: turn peptide
117 <400> SEQUENCE: 7
118 Ser Cys Thr Asn Gln Gly Ser Phe Leu Thr Cys Lys
119   1           5           10
121 <210> SEQ ID NO: 8
122 <211> LENGTH: 12
123 <212> TYPE: PRT
124 <213> ORGANISM: Artificial Sequence
126 <220> FEATURE:
127 <223> OTHER INFORMATION: turn peptide
129 <400> SEQUENCE: 8
130 Ser Cys Gly Trp Gln Gly Ser Phe Leu Thr Cys Lys

```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001
TIME: 15:33:38

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03162001\I592695.raw

```
131      1              5              10
133 <210> SEQ ID NO: 9
134 <211> LENGTH: 12
135 <212> TYPE: PRT
136 <213> ORGANISM: Artificial Sequence
138 <220> FEATURE:
139 <223> OTHER INFORMATION: turn peptide
141 <400> SEQUENCE: 9
142 Ser Cys Thr Trp Gln Gly Ser Phe Leu Thr Cys Lys
143      1              5              10
145 <210> SEQ ID NO: 10
146 <211> LENGTH: 12
147 <212> TYPE: PRT
148 <213> ORGANISM: Artificial Sequence
150 <220> FEATURE:
151 <223> OTHER INFORMATION: turn peptide
153 <400> SEQUENCE: 10
154 Ser Cys Gly Asn Gln Gly Ser Phe Leu Thr Cys Lys
155      1              5              10
157 <210> SEQ ID NO: 11
158 <211> LENGTH: 12
159 <212> TYPE: PRT
160 <213> ORGANISM: Artificial Sequence
162 <220> FEATURE:
163 <223> OTHER INFORMATION: turn peptide
165 <400> SEQUENCE: 11
166 Ser Cys Thr Trp Gln Gly Ser Phe Leu Thr Cys Lys
167      1              5              10
169 <210> SEQ ID NO: 12
170 <211> LENGTH: 10
171 <212> TYPE: PRT
172 <213> ORGANISM: Artificial Sequence
174 <220> FEATURE:
175 <223> OTHER INFORMATION: turn peptide
177 <400> SEQUENCE: 12
178 Cys Thr Lys Val Trp Gln Leu Trp Thr Cys
179      1              5              10
181 <210> SEQ ID NO: 13
182 <211> LENGTH: 12
183 <212> TYPE: PRT
184 <213> ORGANISM: Artificial Sequence
186 <220> FEATURE:
187 <223> OTHER INFORMATION: turn peptide
189 <400> SEQUENCE: 13
190 Ser Cys Thr Trp Val Trp Gln Leu Leu Thr Cys Lys
191      1              5              10
193 <210> SEQ ID NO: 14
194 <211> LENGTH: 12
195 <212> TYPE: PRT
```

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001
 TIME: 15:33:38

Input Set : A:\PTO.txt
 Output Set: N:\CRF3\03162001\I592695.raw

196 <213> ORGANISM: Artificial Sequence
 198 <220> FEATURE:
 199 <223> OTHER INFORMATION: turn peptide
 201 <400> SEQUENCE: 14
 202 Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys
 203 1 5 10
 205 <210> SEQ ID NO: 15
 206 <211> LENGTH: 12
 207 <212> TYPE: PRT
 208 <213> ORGANISM: Artificial Sequence
 210 <220> FEATURE:
 211 <223> OTHER INFORMATION: turn peptide
 213 <400> SEQUENCE: 15
 214 Ser Cys Thr Trp Gly Pro Leu Thr Leu Thr Cys Lys
 215 1 5 10
 217 <210> SEQ ID NO: 16
 218 <211> LENGTH: 10
 219 <212> TYPE: PRT
 220 <213> ORGANISM: Artificial Sequence
 222 <220> FEATURE:
 223 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.
 225 <220> FEATURE:
 226 <221> NAME/KEY: unsure ?
 227 <222> LOCATION: 3
 228 <223> OTHER INFORMATION: unknown amino acid
 230 <400> SEQUENCE: 16
 W-- 231 Cys Thr Xaa Glu Gly Asn Lys Leu Thr Cys
 232 1 5 10
 234 <210> SEQ ID NO: 17
 235 <211> LENGTH: 10
 236 <212> TYPE: PRT
 237 <213> ORGANISM: Artificial Sequence
 239 <220> FEATURE:
 240 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.
 242 <220> FEATURE:
 243 <221> NAME/KEY: unsure
 244 <222> LOCATION: 3
 245 <223> OTHER INFORMATION: unknown amino acid
 247 <400> SEQUENCE: 17
 W--> 248 Cys Thr Xaa Glu Asn Gly Lys Leu Thr Cys
 249 1 5 10
 251 <210> SEQ ID NO: 18
 252 <211> LENGTH: 10
 253 <212> TYPE: PRT
 254 <213> ORGANISM: Artificial Sequence
 256 <220> FEATURE:
 257 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.
 259 <220> FEATURE:
 260 <221> NAME/KEY: unsure

Xaa has been identified as one of the above.

same discrepancy as above

same

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001
TIME: 15:33:38

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03162001\I592695.raw

261 <222> LOCATION: 3
262 <223> OTHER INFORMATION: (unknown amino acid)
264 <400> SEQUENCE: 18
W--> 265 Cys Thr Xaa Glu Pro Asn Lys Leu Thr Cys
266 1 5 10
268 <210> SEQ ID NO: 19
269 <211> LENGTH: 10
270 <212> TYPE: PRT
271 <213> ORGANISM: Artificial Sequence
273 <220> FEATURE:
274 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.
276 <220> FEATURE:
277 <221> NAME/KEY: (unsure)
278 <222> LOCATION: (3)
279 <223> OTHER INFORMATION: (unknown amino acid) same
281 <400> SEQUENCE: 19
W--> 282 Cys Thr Xaa Glu Pro Gly Lys Leu Thr Cys
283 1 5 10
285 <210> SEQ ID NO: 20
286 <211> LENGTH: 10
287 <212> TYPE: PRT
288 <213> ORGANISM: Artificial Sequence
290 <220> FEATURE:
291 <223> OTHER INFORMATION: Xaa is Trp, Tyr, Phe, Leu, Met, Ile, Val or Ala
293 <220> FEATURE:
294 <221> NAME/KEY: (unsure)
295 <222> LOCATION: (3)
296 <223> OTHER INFORMATION: (unknown amino acid) same
298 <400> SEQUENCE: 20
W--> 299 Cys Thr Xaa Glu Gly Asn Lys Leu Thr Cys
300 1 5 10
302 <210> SEQ ID NO: 21
303 <211> LENGTH: 10
304 <212> TYPE: PRT
305 <213> ORGANISM: Artificial Sequence
307 <220> FEATURE:
308 <223> OTHER INFORMATION: Xaa is Trp, Tyr, Phe, Leu, Met, Ile, Val or Ala
310 <220> FEATURE:
311 <221> NAME/KEY: (unsure)
312 <222> LOCATION: (8)
313 <223> OTHER INFORMATION: (unknown amino acid) same
315 <400> SEQUENCE: 21
W--> 316 Cys Thr Leu Glu Gly Asn Lys Xaa Thr Cys
317 1 5 10
319 <210> SEQ ID NO: 22
320 <211> LENGTH: 10
321 <212> TYPE: PRT
322 <213> ORGANISM: Artificial Sequence
324 <220> FEATURE:

Please correct these errors
in subsequent sequences too.

FYI

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001

TIME: 15:33:39

Input Set : A:\PTO.txt


Output Set: N:\CRF3\03162001\I592695.raw

L:30 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:36 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:46 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:231 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:248 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
L:282 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:299 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:316 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:333 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:350 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:382 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25



Patent Docket P 1627R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Andrea G. Cochran et al. Serial No.: 09/592,695 Filed: June 13, 2000 For: Structured Peptide Scaffold for Displaying Turn Libraries on Phage	Group Art Unit: 1627 Examiner: T. Prasthofer CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on October 29, 2001  Eileen Ly
--	---

TECH CENTER 1600/2900

JAN 22 2001

RECEIVED

CERTIFICATE RE: SEQUENCE LISTINGRESPONSE UNDER 37 CFR § 1.821(f) and (g)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: October 29, 2001

By: 

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674



09157

PATENT TRADEMARK OFFICE